You reviewed ....
for this content
out of 5
Event : Heart Failure 2017
Topic : Other
Introduction & remarks.
Heart Failure 2017
Expanding the evidence for rivaroxaban in Atrial Fibrillation (AF) patients with comorbidites including Heart Failure (HF): from Randomized Controlled Trials (RCT) to Real World Evidence (RWE).
Options in thrombosis prevention and vascular health – What’s on the horizon?
Broadening the evidence base for rivaroxaban in heart failure.
Exploring new frontiers: is it time for a comorbidity-based approach in heart failure?
Q&A and closing remarks.
Get your access to resources
Our mission: To reduce the burden of cardiovascular disease